clinical trial · NCT05331885
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Aridis Pharmaceuticals, Inc.·phase3·terminated·n = 24
Ventilator Associated PneumoniaStaphylococcus AureusSuvratoxumabPlacebo
brief summary
Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
started
Sep 2, 2022
primary completion
Jul 8, 2024
completion
Jul 8, 2024
last updated
Mar 24, 2025
detailed description
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy of a single IV dose of suvratoxumab in mechanically ventilated subjects in the ICU who are at high risk for S. aureus infections and who are currently free of active S. aureus-related disease but are colonized with S. aureus in the LRT.
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol